Scholarlink

Background <p>Eicosanoids are a diverse family of oxygenated derivatives of 20-carbon polyunsaturated fatty acids that play crucial roles in maintaining cardiovascular homeostasis. The metabolic profiles of eicosanoids preceding the onset of severe preeclampsia remain incompletely understood. This study aimed to use a targeted metabolomic approach to identify eicosanoid metabolites in first-trimester blood samples and assess their potential to predict severe preeclampsia.</p> Methods <p>Within a prospective cohort of 5,809 pregnant women, a nested case-control study analyzed 45 participants who later developed severe preeclampsia and 41 controls with uncomplicated pregnancies. Targeted metabolomic analysis was performed using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS). Metabolomic data were examined, and predictive performance of these metabolites was evaluated using receiver operating characteristic curves.</p> Results <p>Among 40 eicosanoids metabolites quantified, 10 metabolites differed statistically between the severe preeclampsia and control groups. Specifically, metabolites in the cyclooxygenase (COX) pathway, such as thromboxane B2 (TXB2), and the 12/15-lipoxygenase (LOX) pathway, such as 14-hydroxy-docosahexaenoic acid (14-HDoHE), were significantly upregulated in the severe preeclampsia group. Conversely, metabolites in the cytochrome P450 (CYP450) pathway, notably 19,20-epoxy-docosapentaenoic acid (19,20-EDP), were significantly downregulated. The 14-HDoHE/19,20-EDP ratio was identified as the most significant predictive marker. Integrating this ratio into the Fetal Medicine Foundation (FMF) screening algorithms significantly improved the area under the curve (AUC) from 0.77 to 0.87 (ΔAUC = 0.10, 95% confidence interval [CI]: 0.03–0.18, <i>P</i> = 0.008). This combined model demonstrated a sensitivity of 0.73 (95% CI: 0.60–0.86) and a specificity of 0.85 (95% CI: 0.75–0.96).</p> Conclusions <p>Our findings revealed novel prediction models for severe preeclampsia based on first-trimester eicosanoid metabolomics, and provide mechanistic evidence supporting early aspirin use for COX pathway inhibition and suggest that rebalancing the 12/15-LOX and CYP450 pathways may be a potential strategy for preventing severe preeclampsia.</p> Trial registration <p>Chinese Clinical Trial Registry Identifier ChiCTR-EOC-15007644, registered on 03 December 2015.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First-trimester plasma targeted metabolomics for eicosanoids reveals predictive potential and preventive targets for severe preeclampsia: a nested case-control study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Yongqiang Ma,
  • Linjie Li,
  • Yiwen Fang,
  • Wei Cai,
  • Jingbo Yang,
  • Liuyang Zhang,
  • Lushu Zuo,
  • Xiulong Niu,
  • Shaobo Chen,
  • Qing Yang,
  • Ying Yu,
  • Cha Han,
  • Hongliang Cong,
  • Xu Zhang,
  • Xin Zhou

摘要

Background

Eicosanoids are a diverse family of oxygenated derivatives of 20-carbon polyunsaturated fatty acids that play crucial roles in maintaining cardiovascular homeostasis. The metabolic profiles of eicosanoids preceding the onset of severe preeclampsia remain incompletely understood. This study aimed to use a targeted metabolomic approach to identify eicosanoid metabolites in first-trimester blood samples and assess their potential to predict severe preeclampsia.

Methods

Within a prospective cohort of 5,809 pregnant women, a nested case-control study analyzed 45 participants who later developed severe preeclampsia and 41 controls with uncomplicated pregnancies. Targeted metabolomic analysis was performed using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS). Metabolomic data were examined, and predictive performance of these metabolites was evaluated using receiver operating characteristic curves.

Results

Among 40 eicosanoids metabolites quantified, 10 metabolites differed statistically between the severe preeclampsia and control groups. Specifically, metabolites in the cyclooxygenase (COX) pathway, such as thromboxane B2 (TXB2), and the 12/15-lipoxygenase (LOX) pathway, such as 14-hydroxy-docosahexaenoic acid (14-HDoHE), were significantly upregulated in the severe preeclampsia group. Conversely, metabolites in the cytochrome P450 (CYP450) pathway, notably 19,20-epoxy-docosapentaenoic acid (19,20-EDP), were significantly downregulated. The 14-HDoHE/19,20-EDP ratio was identified as the most significant predictive marker. Integrating this ratio into the Fetal Medicine Foundation (FMF) screening algorithms significantly improved the area under the curve (AUC) from 0.77 to 0.87 (ΔAUC = 0.10, 95% confidence interval [CI]: 0.03–0.18, P = 0.008). This combined model demonstrated a sensitivity of 0.73 (95% CI: 0.60–0.86) and a specificity of 0.85 (95% CI: 0.75–0.96).

Conclusions

Our findings revealed novel prediction models for severe preeclampsia based on first-trimester eicosanoid metabolomics, and provide mechanistic evidence supporting early aspirin use for COX pathway inhibition and suggest that rebalancing the 12/15-LOX and CYP450 pathways may be a potential strategy for preventing severe preeclampsia.

Trial registration

Chinese Clinical Trial Registry Identifier ChiCTR-EOC-15007644, registered on 03 December 2015.

Graphical Abstract